0.00Open4.60Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-4.70%PremiumMay 17, 2024Expiry Date4.95Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.62Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cognyte Software Stock Discussion
NEWS
Cognyte to Participate in the TD Cowen 52nd Annual Technology, Media & Telecom Conference
Cognyte Software (NASDAQ: CGNT) announced that its CEO, Elad Sharon, and CFO, David Abadi, will participate in an in-person fireside chat at the TD Cowen 52nd Annual Technology, Media & Telecom Conference.
The event will occur on Wednesday, May 29, 2024, at 10:15am ET. An online, real-time webcast and replay of the discussion will be available on Cognyte's investor relations...
$Pfizer(PFE.US)$ — The biopharmaceutical stock dropped 7.4% after Pfizer issued full-year guidance for adjusted earnings ...
$Target(TGT.US)$ +1.14% (Target announced it would increase its dividend by 1.9%, or 2 cents, to $1.10 per share.)
$Aldeyra Therapeutics(ALDX.US)$ +7.89% (Aldeyra announced it say statistical significance in the primary and all secondary endpoints for a drug that could be used for a type of eye inflammation.)
$Domino's Pizza(DPZ.US)$ +2.31% (The pizza chain rose 2.3% following an upgrade to buy from hold by Stifel. The firm ...
In company news, Cognyte Software $Cognyte Software(CGNT.US)$ rose almost 14% after the investigative analytics software firm Wednesday reported a non-GAAP loss of $0.04 per share in Q2, reversing a $0.17 per share adjusted p...
In reaction to earnings/guidance:
• $Thor Industries(THO.US)$ +2.5%
Other news:
• $Acumen Pharmaceuticals(ABOS.US)$+76.8% (in response with BIIB)
• $Biogen(BIIB.US)$ +45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint)
• $Nano X Imaging(NNOX.US)$+22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multisource 3D digital tomosynthesis system)
• $Ocugen(OCGN.US)$ +9.3% (en...
• $Cadence Design Systems(CDNS.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $175 (from $160)
• $Federated Hermes(FHI.US)$ : KBW Upgrades to Outperform from Market Perform - PT $540
• $Goldman Sachs(GS.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $380 (from $360)
• $McDonald's(MCD.US)$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $278 (from $245)
• $Oracle(ORCL.US)$ : Exane Upg...
• $Kezar Life Sciences(KZR.US)$ +92% (announces positive top line results from the MISSION Phase 2 trial)
• $Sutro Biopharma(STRO.US)$ +24.5% (Sutro Biopharma and Astellas to collaborate to advance novel immunostimulatory antibody-drug conjugates)
• $Ceragon(CRNT.US)$ +17.7% (AVNW to acquire all shares of CRNT that it does not already own for $2.80/sh)
• $Trip.com(TCOM.US)$ +15.6% (In reaction to earnings/guidance)
• $Apyx Medical(APYX.US)$ +8% (anno...
No comment yet